Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2014 Apr 3

PMID 24690569

Citations 38

Authors

R D Harvey

Affiliations

Soon will be listed here.

Abstract

Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial trials. This article reviews the preclinical evidence, rationale, and clinical pharmacology of blockade of PD-1 or its ligands as therapy for lung cancer and provides an overview of agents in development, clinical evidence to date, and implications for clinical application.

Citing Articles

Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience.

Park S, Lee H, Lee S, Hong R In Vivo. 2023; 37(1):233-241.

PMID: 36593005 PMC: 9843772. DOI: 10.21873/invivo.13072.

Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy.

Ghaderi S, Riazi-Rad F, Safaie Qamsari E, Bagheri S, Rahimi-Jamnani F, Sharifzadeh Z BMC Biotechnol. 2022; 22(1):22.

PMID: 35996120 PMC: 9396865. DOI: 10.1186/s12896-022-00752-8.

Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.

Liu Y, Huang B, Lin C, Shen C, Lai S, Chen C Cancers (Basel). 2021; 13(17).

PMID: 34503167 PMC: 8430966. DOI: 10.3390/cancers13174357.

Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.

Lim H, Ramjeesingh R, Liu D, Tam V, Knox J, Card P J Natl Cancer Inst. 2020; 113(2):123-136.

PMID: 32898239 PMC: 7850551. DOI: 10.1093/jnci/djaa119.

Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

Melosky B, Cheema P, Brade A, McLeod D, Liu G, Price P Oncologist. 2020; 25(11):981-992.

PMID: 32860288 PMC: 7648366. DOI: 10.1634/theoncologist.2020-0193.

References

Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H . Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13(7):2151-7. DOI: 10.1158/1078-0432.CCR-06-2746. View

Mangsbo S, Sandin L, Anger K, Korman A, Loskog A, Totterman T . Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010; 33(3):225-35. DOI: 10.1097/CJI.0b013e3181c01fcb. View

Bang Y . The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol. 2011; 3(6):279-91. PMC: 3210468. DOI: 10.1177/1758834011419002. View

Saenger Y, Wolchok J . The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 2008; 8:1. PMC: 2935787. View

Mcdermott D, Atkins M . PD-1 as a potential target in cancer therapy. Cancer Med. 2014; 2(5):662-73. PMC: 3892798. DOI: 10.1002/cam4.106. View

Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C . Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol. 2009; 35(4):741-9. DOI: 10.3892/ijo_00000387. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M . Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005; 65(3):1089-96. View

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-44. PMC: 4126516. DOI: 10.1056/NEJMoa1305133. View

10.

Weber J . Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007; 12(7):864-72. DOI: 10.1634/theoncologist.12-7-864. View

11.

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

12.

Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Perez J . Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007; 7(1):3-18. DOI: 10.2174/187152007779314044. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Rozali E, Hato S, Robinson B, Lake R, Lesterhuis W . Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012; 2012:656340. PMC: 3350956. DOI: 10.1155/2012/656340. View

15.

Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H . Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol. 2010; 185(9):5082-92. PMC: 3077721. DOI: 10.4049/jimmunol.1001821. View

16.

Christensen H, Hermann M . Immunological response as a source to variability in drug metabolism and transport. Front Pharmacol. 2012; 3:8. PMC: 3277081. DOI: 10.3389/fphar.2012.00008. View

17.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

18.

Iwai Y, Terawaki S, Honjo T . PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2004; 17(2):133-44. DOI: 10.1093/intimm/dxh194. View

19.

Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J . PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009; 21(9):1065-77. PMC: 2731790. DOI: 10.1093/intimm/dxp072. View

20.

West E, Jin H, Rasheed A, Penaloza-MacMaster P, Ha S, Tan W . PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013; 123(6):2604-15. PMC: 3668811. DOI: 10.1172/JCI67008. View